Lokaliseret lipohypertrophia under behandling med vaeksthormon

Henriette Mersebach, Ulla F Feldt-Rasmussen


    Accumulation of subcutaneous fat is described in a 51-year-old woman with panhypopituitarism treated on all insufficient pituitary axes, including growth hormone (GH). Malnutrition and alcoholic liver disease caused reduced synthesis of hepatic insulin-like growth factor I (IGF-I), and the function of IGF-I as biochemical marker of the GH effect was compromised. Peripheral levels of GH and IGF-I in tissues may have reached supra physiological levels and induced localised lipohypertrophy. Adjustment of GH treatment should not rest in all cases on IGF-I alone, but also depend on the clinical effect. Adjustment should follow suspected adverse events, such as lipohypertrophy, which is, however, an unusual complication of GH therapy.

    Bidragets oversatte titelLocalized lipohypertrophy during growth hormone therapy
    TidsskriftUgeskrift for Laeger
    Udgave nummer14
    Sider (fra-til)1930-2
    Antal sider3
    StatusUdgivet - 1 apr. 2002


    • Adipose Tissue/drug effects
    • Female
    • Growth Hormone/administration & dosage
    • Humans
    • Hypertrophy/chemically induced
    • Insulin-Like Growth Factor I/metabolism
    • Lipodystrophy/chemically induced
    • Middle Aged


    Dyk ned i forskningsemnerne om 'Lokaliseret lipohypertrophia under behandling med vaeksthormon'. Sammen danner de et unikt fingeraftryk.